AANPCB Board Prep/Plan
๐Ÿ“

Plan

Evidence-based treatment plans, pharmacotherapy and psychotherapy selection, level of care decisions, referrals, and patient education.

335 questions ยท AANPCB: 26% of exam
What the AANPCB tests in Planโ–ถ

The Plan domain accounts for 26% of scored questions on the AANPCB PMHNP-C exam. It tests your ability to establish collaborative, patient-centered, evidence-based treatment plans that integrate pharmacotherapy, psychotherapy, level-of-care decisions, referrals, and patient education.

Questions in this domain cover the full scope of treatment planning: selecting first-line medications, choosing appropriate psychotherapy modalities, providing informed consent (including risks, benefits, and alternatives), determining level of care, making referrals, and educating patients. The AANPCB tests whether you can build a complete treatment plan, not just prescribe a medication.

The Plan domain also tests monitoring adherence while considering barriers โ€” financial constraints, cultural factors, side effects, and access to care. A technically correct medication choice can be the wrong answer if the patient context makes it impractical. Safety planning, crisis intervention, and care transitions are also tested here.

Practice Plan Questions

Build a custom quiz and track your performance across all four AANPCB process domains. Free account required.

Build a Quiz

All 335 questions

1.
SSRI Mechanism of Action and Selection
beginnerSSRImechanism of actionmajor depressive disorder
โ†’
2.
SSRI Discontinuation Syndrome Management
beginnerSSRI discontinuationparoxetinetaper
โ†’
3.
Clozapine ANC Monitoring Requirements
intermediateclozapineANC monitoringagranulocytosis
โ†’
4.
CYP450 Drug Interaction: Fluvoxamine and Clozapine
advancedCYP1A2fluvoxamineclozapine
โ†’
5.
Lamotrigine Titration and Stevens-Johnson Risk
intermediatelamotrigineStevens-Johnson syndromebipolar depression
โ†’
6.
Benzodiazepine Equivalency and Taper Strategy
advancedbenzodiazepine taperdiazepam equivalencyalprazolam
โ†’
7.
Stimulant Prescribing in ADHD with Cardiac History
advancedstimulant prescribingADHDcardiac screening
โ†’
8.
First-Line SSRI Selection for MDD
beginnerMDDSSRIpharmacotherapy
โ†’
9.
Augmentation Strategies for Treatment-Resistant Depression
intermediatetreatment-resistant depressionaugmentationaripiprazole
โ†’
10.
First-Line Pharmacotherapy for Acute Mania
intermediatebipolar disorderacute manialithium
โ†’
11.
Medication Selection for Comorbid Anxiety and Depression
beginnercomorbidityGADMDD
โ†’
12.
Level of Care Criteria: Inpatient vs. Outpatient
beginnersuicide risk assessmentlevel of careinpatient
โ†’
13.
Collaborative Care Model Roles
intermediatecollaborative careCoCMintegrated care
โ†’
14.
Clozapine Indication in Treatment-Resistant Schizophrenia
advancedclozapinetreatment-resistant schizophreniaANC monitoring
โ†’
15.
CBT for Panic Disorder: Core Techniques
intermediateCBTpanic disorderinteroceptive exposure
โ†’
16.
DBT Skills for Borderline Personality Disorder
intermediateDBTborderline personality disorderdistress tolerance
โ†’
17.
Motivational Interviewing in Substance Use
beginnermotivational interviewingsubstance use disorderalcohol use disorder
โ†’
18.
Prolonged Exposure vs. EMDR for PTSD
advancedPTSDprolonged exposureEMDR
โ†’
19.
PMHNP Scope of Practice and Prescriptive Authority
beginnerscope of practiceprescriptive authorityPMHNP
โ†’
20.
Collaborative Practice Agreement Requirements and Components
intermediatecollaborative practice agreementreduced practice authorityprescriptive authority
โ†’
21.
Documentation Standards for Comprehensive Psychiatric Evaluation
beginnerdocumentationpsychiatric evaluationrisk assessment
โ†’
22.
Telehealth Prescribing Regulations for Controlled Substances
advancedtelehealthcontrolled substancesprescribing regulations
โ†’
23.
Tarasoff Duty to Warn and Protect Third Parties
intermediateTarasoffduty to warnduty to protect
โ†’
24.
Involuntary Psychiatric Hold Criteria and Legal Standards
intermediateinvoluntary holdpsychiatric emergencycivil commitment
โ†’
25.
Informed Consent for Psychotropic Medication Prescribing
beginnerinformed consentlithiumbipolar disorder
โ†’
26.
Antidepressant Use in Pregnancy: SSRI Safety and Risk-Benefit Analysis
advancedpregnancySSRIsertraline
โ†’
27.
Geriatric Psychopharmacology and the AGS Beers Criteria
intermediateBeers Criteriageriatricanticholinergic
โ†’
28.
Pediatric Black Box Warning: Antidepressants and Suicidality Risk
beginnerblack box warningpediatric depressionfluoxetine
โ†’
29.
Venlafaxine Selection for Comorbid Depression and Chronic Pain
intermediatevenlafaxineSNRIfibromyalgia
โ†’
30.
Quetiapine Off-Label Use for Insomnia: Risks and Appropriateness
beginnerquetiapineoff-label prescribinginsomnia
โ†’
31.
Naltrexone vs Acamprosate for Alcohol Use Disorder
intermediatenaltrexoneacamprosatealcohol use disorder
โ†’
32.
Prazosin for PTSD-Related Nightmares
beginnerprazosinPTSDnightmares
โ†’
33.
Trazodone Mechanism and Appropriate Use for Insomnia
beginnertrazodoneSARIinsomnia
โ†’
34.
Valproate Teratogenicity and Pregnancy Counseling
advancedvalproateteratogenicitypregnancy
โ†’
35.
Long-Acting Injectable Antipsychotics: Indications and Advantages
advancedlong-acting injectableantipsychoticschizophrenia
โ†’
36.
Buspirone Mechanism and Clinical Niche
beginnerbuspirone5-HT1A partial agonistgeneralized anxiety disorder
โ†’
37.
Switching Antidepressants: Washout Periods and Cross-Titration
intermediateantidepressant switchingwashout periodfluoxetine
โ†’
38.
Methylphenidate vs Amphetamine: Pharmacological Differences
advancedmethylphenidateamphetamineADHD
โ†’
39.
Bupropion NDRI Mechanism and Dual Indications
beginnerbupropionNDRIsmoking cessation
โ†’
40.
Mirtazapine Receptor Profile, Weight Gain, and Sedation
intermediatemirtazapineNaSSAH1 antagonism
โ†’
41.
Duloxetine for Comorbid Depression and Chronic Pain
beginnerduloxetineSNRIdiabetic neuropathy
โ†’
42.
Clonidine vs Guanfacine for ADHD: Alpha-2 Agonist Comparison
intermediateclonidineguanfacinealpha-2 agonist
โ†’
43.
Atomoxetine Mechanism and Monitoring for ADHD
intermediateatomoxetinenorepinephrine reuptake inhibitorADHD
โ†’
44.
Naltrexone Oral vs Injectable for AUD and OUD
advancednaltrexoneVivitrolinjectable
โ†’
45.
Gabapentin vs Pregabalin: Pharmacokinetic Differences
intermediategabapentinpregabalinpharmacokinetics
โ†’
46.
Hydroxyzine vs Diphenhydramine for Anxiety
beginnerhydroxyzinediphenhydramineantihistamine
โ†’
47.
Propranolol for Performance Anxiety
beginnerpropranololbeta-blockerperformance anxiety
โ†’
48.
Valproate Laboratory Monitoring and Hepatotoxicity Risk
intermediatevalproatelaboratory monitoringhepatotoxicity
โ†’
49.
Aripiprazole Partial Dopamine Agonism Mechanism
intermediatearipiprazolepartial agonistdopamine stabilizer
โ†’
50.
Quetiapine Dose-Dependent Receptor Binding
advancedquetiapinedose-dependent bindingreceptor hierarchy
โ†’
51.
Long-Acting Injectable Antipsychotics: Oral Overlap and Loading Strategy
advancedpaliperidone palmitatelong-acting injectableloading dose
โ†’
52.
Stepped Care Model for Depression
beginnerstepped caremild depressionPHQ-9
โ†’
53.
Augment vs. Switch: Antidepressant Partial Response
intermediateaugmentationswitchingpartial response
โ†’
54.
Treatment Planning for Depression with Alcohol Use Disorder
intermediatedual diagnosisalcohol use disorderMDD
โ†’
55.
Relapse Prevention Planning for Bipolar Disorder
intermediatebipolar disorderrelapse preventionlithium
โ†’
56.
Stanley-Brown Safety Planning Intervention
beginnersafety planningStanley-Brownsuicide prevention
โ†’
57.
Motivational Interviewing in Treatment Planning
intermediatemotivational interviewingOARSambivalence
โ†’
58.
Cultural Considerations in Medication Selection
intermediatecultural considerationspharmacogenomicsCYP2C19
โ†’
59.
Shared Decision-Making with Treatment-Resistant Depression
advancedshared decision-makingtreatment-resistant depressionpatient autonomy
โ†’
60.
Tapering Plan for Long-Term Benzodiazepine Use
advancedbenzodiazepine taperingclonazepamdiazepam
โ†’
61.
ECT Indications and Treatment Planning
advancedECTpsychotic depressiontreatment-resistant depression
โ†’
62.
CBT for Panic: Cognitive Restructuring of Catastrophic Misinterpretations
beginnerCBTpanic disordercognitive restructuring
โ†’
63.
DBT Interpersonal Effectiveness: DEAR MAN
intermediateDBTinterpersonal effectivenessDEAR MAN
โ†’
64.
ERP for OCD: Contamination Obsessions
intermediateOCDERPexposure and response prevention
โ†’
65.
EMDR: The Eight-Phase Protocol
advancedEMDRPTSDeight phases
โ†’
66.
Supportive vs. Insight-Oriented Psychotherapy
beginnersupportive psychotherapyinsight-oriented therapyschizophrenia
โ†’
67.
Solution-Focused Brief Therapy: The Miracle Question
intermediatesolution-focused brief therapymiracle questionde Shazer
โ†’
68.
Cognitive Processing Therapy: Stuck Points in Trauma
advancedCPTcognitive processing therapyPTSD
โ†’
69.
Behavioral Activation for Depression
intermediatebehavioral activationdepressionactivity scheduling
โ†’
70.
DEA Registration and Controlled Substance Prescriptive Authority
beginnerDEA registrationcontrolled substancesprescriptive authority
โ†’
71.
Peer Consultation and Clinical Supervision in PMHNP Practice
beginnerpeer consultationclinical supervisionprofessional practice
โ†’
72.
Evidence-Based Practice: Hierarchy of Evidence
beginnerevidence-based practicehierarchy of evidencesystematic review
โ†’
73.
Quality Improvement in Psychiatric Practice
intermediatequality improvementmeasurement-based carePHQ-9
โ†’
74.
HIPAA Exceptions in Psychiatric Emergencies
intermediateHIPAAconfidentialitypsychiatric emergency
โ†’
75.
Mandatory Reporting of Suspected Child Abuse
beginnermandatory reportingchild abuseCPS
โ†’
76.
Patient Autonomy vs Beneficence in Treatment Refusal
intermediateautonomybeneficencetreatment refusal
โ†’
77.
Genetic Information Nondiscrimination Act (GINA) Protections
advancedGINAgenetic discriminationpharmacogenomics
โ†’
78.
Ethical Considerations in Prescribing to Family Members
beginnerprescribing ethicsdual relationshipsfamily members
โ†’
79.
Antidepressant Prescribing During Breastfeeding
intermediatebreastfeedingsertralinepostpartum depression
โ†’
80.
Opioid Use Disorder in Pregnancy and Neonatal Abstinence Syndrome
intermediateOUDpregnancybuprenorphine
โ†’
81.
Gabapentin vs Pregabalin: Abuse Potential and Scheduling Differences
intermediategabapentinpregabalinabuse potential
โ†’
82.
Hydroxyzine for Anxiety: Mechanism and Clinical Limitations
beginnerhydroxyzineH1 antagonistgeneralized anxiety disorder
โ†’
83.
Duloxetine Analgesic Mechanism: Descending Pain Inhibition via Norepinephrine
intermediateduloxetineanalgesic mechanismdescending pain pathways
โ†’
84.
Propranolol for Performance Anxiety: Mechanism and Asthma Contraindication
beginnerpropranololperformance anxietybeta-blocker
โ†’
85.
Stimulant Class Switch After Methylphenidate Failure: Clinical Rationale
intermediatemethylphenidateamphetamineADHD
โ†’
86.
SSRI Selection for OCD in a Patient on Clozapine: Managing the CYP1A2 Interaction
advancedclozapinefluvoxamineCYP1A2
โ†’
87.
Ramelteon: Melatonin Receptor Agonism and Absence of Abuse Potential
intermediateramelteonmelatonin receptor agonistinsomnia
โ†’
88.
Dextromethorphan-Bupropion (Auvelity): NMDA Mechanism for Depression
advanceddextromethorphan-bupropionAuvelityNMDA antagonist
โ†’
89.
Pimozide QTc Prolongation and CYP2D6 Inhibitor Contraindication
advancedpimozideQTc prolongationCYP2D6
โ†’
90.
Measurement-Based Care: Evidence for Implementation Over Clinical Judgment Alone
intermediatemeasurement-based carequality improvementPHQ-9
โ†’
91.
Treatment of Comorbid PTSD and Substance Use Disorder
intermediatePTSDsubstance use disorderintegrated treatment
โ†’
92.
Motivational Interviewing and Stages of Change Framework
intermediatemotivational interviewingstages of changecontemplation
โ†’
93.
SSRI Discontinuation Syndrome and Tapering Principles
intermediateSSRI discontinuation syndromeparoxetinetapering
โ†’
94.
Augmentation Strategies for Treatment-Resistant OCD
advancedtreatment-resistant OCDaugmentationrisperidone
โ†’
95.
Clozapine Initiation Criteria and Monitoring Requirements
advancedclozapineANC monitoring protocolANC monitoring
โ†’
96.
Light Therapy for Seasonal Affective Disorder
beginnerseasonal affective disorderlight therapycircadian rhythm
โ†’
97.
Eating Disorder Level of Care: Medical Instability Criteria
intermediateanorexia nervosalevel of caremedical stabilization
โ†’
98.
Integrating Peer Support Specialists into Treatment Planning
beginnerpeer supportrecovery modelserious mental illness
โ†’
99.
Opioid Use Disorder: Methadone vs. Buprenorphine Treatment Selection
intermediateopioid use disordermethadonebuprenorphine
โ†’
100.
Integrated vs. Sequential Treatment for Dual Diagnosis
intermediatedual diagnosisintegrated treatmentco-occurring disorders
โ†’
101.
Suicide Risk Stratification and Disposition Decision-Making
advancedsuicide risk stratificationdispositioninvoluntary admission
โ†’
102.
Medication Management During an ECT Course
advancedECTlithiumbenzodiazepine
โ†’
103.
Tobacco Cessation Pharmacotherapy Selection
beginnertobacco cessationvareniclinesmoking
โ†’
104.
Step-Down from Inpatient to Partial Hospitalization: Transition Planning
intermediatepartial hospitalizationstep-down caredischarge planning
โ†’
105.
Prolonged Exposure: In Vivo vs. Imaginal Exposure
intermediateprolonged exposurePTSDimaginal exposure
โ†’
106.
CBT-I: Sleep Restriction and Stimulus Control
beginnerCBT-Iinsomniasleep restriction
โ†’
107.
Schema Therapy: Early Maladaptive Schemas in Personality Disorders
advancedschema therapyearly maladaptive schemaspersonality disorders
โ†’
108.
Supportive Psychotherapy: Techniques in Acute Crisis
beginnersupportive psychotherapycrisis interventionadaptive defenses
โ†’
109.
Trauma-Focused CBT for Children: The Trauma Narrative Component
intermediateTF-CBTchild traumatrauma narrative
โ†’
110.
Narrative Therapy: Externalization and Unique Outcomes
intermediatenarrative therapyexternalizationunique outcomes
โ†’
111.
Relapse Prevention: Marlatt's High-Risk Situations Model
intermediaterelapse preventionMarlatthigh-risk situations
โ†’
112.
Psychoeducation as an Evidence-Based Therapeutic Intervention
beginnerpsychoeducationbipolar disordertreatment adherence
โ†’
113.
Play Therapy: Developmental Rationale in Child Psychiatry
advancedplay therapychild psychiatrydevelopmental psychology
โ†’
114.
Acetylcholine and the Cholinergic Hypothesis of Alzheimer's Disease
beginneracetylcholineAlzheimer's diseasedonepezil
โ†’
115.
Opioid Receptor Subtypes and Their Behavioral Effects
intermediateopioid receptorsbuprenorphinemethadone
โ†’
116.
First-Pass Metabolism and Oral Drug Bioavailability
beginnerfirst-pass metabolismbioavailabilitypharmacokinetics
โ†’
117.
Against Medical Advice Discharge: Documentation and Risk Assessment
intermediateAMA dischargedocumentationrisk assessment
โ†’
118.
Substituted Judgment vs Best Interest Standard for Incapacitated Patients
advancedsubstituted judgmentbest interestsurrogate decision-making
โ†’
119.
Reporting Impaired Colleagues: Ethical and Legal Duty
intermediateimpaired colleagueduty to reportpatient safety
โ†’
120.
21st Century Cures Act: Patient Access to Psychiatric Records
advanced21st Century Cures Actinformation blockingpsychotherapy notes
โ†’
121.
Involuntary Medication: Sell v. United States Principles
advancedSell v. United Statesinvoluntary medicationcompetency restoration
โ†’
122.
Managing Boundaries in Rural and Small Community Practice
intermediaterural practicedual relationshipsboundary management
โ†’
123.
Research Ethics: Vulnerable Populations in Psychiatric Research
advancedresearch ethicsvulnerable populationsinformed consent
โ†’
124.
Genetic Testing in Psychiatry: Consent and Implications
advancedgenetic testinginformed consentwhole-exome sequencing
โ†’
125.
Breastfeeding and Psychiatric Medications: Risk Framework
intermediatebreastfeedingsertralinerelative infant dose
โ†’
126.
Substance Use in Pregnancy: Neonatal Abstinence Syndrome
advancedpregnancyopioid use disorderbuprenorphine
โ†’
127.
Homeless Population: Treatment Barriers and Adaptations
intermediatehomelessnessschizophreniaLAI antipsychotic
โ†’
128.
Incarcerated Patients: Psychiatric Care Considerations
advancedcorrectional psychiatryEstelle v. Gambleincarceration
โ†’
129.
Interprofessional Collaboration: Communicating with Primary Care
beginnerinterprofessional collaborationprimary carequetiapine
โ†’
130.
Documentation Standards: Psychiatric Progress Notes
beginnerdocumentationprogress notesmedical records
โ†’
131.
Telehealth Prescribing: Ryan Haight Act Requirements
intermediatetelehealthRyan Haight Actcontrolled substances
โ†’
132.
Clinical Supervision Models: Administrative vs Clinical
beginnerclinical supervisionadministrative supervisionprofessional development
โ†’
133.
Caseload Management: Productivity vs Quality of Care
intermediatecaseload managementproductivitypatient safety
โ†’
134.
Bupropion Contraindication in Bulimia Nervosa
beginnerbupropionseizure thresholdbulimia nervosa
โ†’
135.
Mood Stabilizer Teratogenicity: Valproate vs Lamotrigine in Pregnancy Planning
advancedvalproatelamotrigineteratogenicity
โ†’
136.
Naltrexone and Emergency Pain Management: Perioperative Considerations
advancednaltrexoneVivitrolperioperative management
โ†’
137.
Buspirone Limitations: Ineffective for Panic Disorder
intermediatebuspironepanic disordergeneralized anxiety disorder
โ†’
138.
Lithium Augmentation in Treatment-Resistant Depression
intermediatetreatment-resistant depressionlithium augmentationTRD
โ†’
139.
Stepped Care Model for Generalized Anxiety Disorder
beginnerstepped caregeneralized anxiety disorderGAD-7
โ†’
140.
Relapse Prevention Planning for Alcohol Use Disorder
intermediaterelapse preventionalcohol use disordersubstance use disorders
โ†’
141.
ECT Indications for Catatonic Depression
advancedECTelectroconvulsive therapycatatonia
โ†’
142.
Treatment Planning for Comorbid PTSD and Substance Use
advancedPTSDsubstance use disordercomorbid treatment
โ†’
143.
Shared Decision-Making in Antipsychotic Selection
intermediateshared decision-makingantipsychoticshyperprolactinemia
โ†’
144.
Motivational Interviewing: OARS in the Contemplation Stage
beginnermotivational interviewingOARSstages of change
โ†’
145.
ACT: Psychological Flexibility and Experiential Avoidance
intermediateACTacceptance and commitment therapypsychological flexibility
โ†’
146.
Supportive Psychotherapy vs Insight-Oriented Therapy
beginnersupportive psychotherapyinsight-oriented therapyschizophrenia
โ†’
147.
Trauma-Focused CBT for Children: Managing the Trauma Narrative
intermediateTF-CBTtrauma-focused CBTchildren
โ†’
148.
IPT for Depression: Role Disputes and Communication Analysis
advancedinterpersonal therapyIPTdepression
โ†’
149.
Involuntary Commitment for Grave Disability
beginnerinvoluntary commitmentgrave disabilitybipolar mania
โ†’
150.
HIPAA Emergency Disclosure on an Inpatient Unit
intermediateHIPAAemergency disclosureminimum necessary standard
โ†’
151.
Boundary Violation: Social Media Contact with a Patient
beginnerboundary violationboundary crossingsocial media
โ†’
152.
Mandatory Reporting of Elder Abuse by a Caregiver
advancedmandatory reportingelder abuseneglect
โ†’
153.
Patient Autonomy vs Beneficence in Severe Eating Disorder
intermediateautonomybeneficenceanorexia nervosa
โ†’
154.
Prescriptive Authority and Collaborative Practice Agreement Scope
advancedprescriptive authoritycollaborative practice agreementscope of practice
โ†’
155.
ADHD Medication Management During Pregnancy
intermediateADHDpregnancystimulant medications
โ†’
156.
Telehealth Controlled Substance Prescribing Requirements
intermediatetelehealthcontrolled substancesRyan Haight Act
โ†’
157.
Clinical Supervision Models in PMHNP Professional Development
beginnerclinical supervisionProctor's modelprofessional development
โ†’
158.
Quality Improvement Using PDSA Cycles in Psychiatric Practice
intermediatequality improvementPDSAreadmission reduction
โ†’
159.
Burnout Intervention: Why Individual Strategies Alone Are Insufficient
advancedburnoutorganizational interventionsMaslach Burnout Inventory
โ†’
160.
CBASP for Chronic Depression: Situational Analysis
beginnerCBASPchronic depressionpersistent depressive disorder
โ†’
161.
Interpersonal and Social Rhythm Therapy for Bipolar Disorder
intermediateIPSRTbipolar disordersocial rhythm metric
โ†’
162.
Functional Analytic Psychotherapy: In-Session Behavior Change
intermediatefunctional analytic psychotherapyFAPclinically relevant behavior
โ†’
163.
Dialectical Abstinence in DBT for Substance Use Disorders
advancedDBTsubstance use disorderdialectical abstinence
โ†’
164.
Parent-Child Interaction Therapy: CDI Phase
intermediatePCITparent-child interaction therapyoppositional defiant disorder
โ†’
165.
Multisystemic Therapy for Juvenile Offenders
beginnermultisystemic therapyMSTconduct disorder
โ†’
166.
Emotionally Focused Therapy for Couples: Attachment Cycles
advancedemotionally focused therapyEFTcouples therapy
โ†’
167.
Harm Reduction Psychotherapy Framework
intermediateharm reductionsubstance use disorderalcohol use disorder
โ†’
168.
Compassion-Focused Therapy: Addressing Shame and Self-Criticism
advancedcompassion-focused therapyCFTshame
โ†’
169.
Brief Psychodynamic Therapy: Core Conflictual Relationship Theme
intermediatebrief psychodynamic therapyCCRTLuborsky
โ†’
170.
MBCT for Depression Relapse Prevention: Decentering
intermediateMBCTmindfulnessdepression relapse prevention
โ†’
171.
Informed Consent for Psychiatric Medication Prescribing
intermediateinformed consentlithiumdocumentation
โ†’
172.
HIPAA Protections for Psychiatric Records and Psychotherapy Notes
intermediateHIPAAconfidentialitypsychotherapy notes
โ†’
173.
Professional Boundaries and Dual Relationships in Psychiatric Practice
advancedprofessional boundariesdual relationshipsrural practice
โ†’
174.
Credentialing and Privileging for PMHNPs in Healthcare Organizations
beginnercredentialingprivilegingCMS
โ†’
175.
Forensic Role Boundaries: Treating Clinician vs Forensic Evaluator
intermediateforensic evaluationdual rolescustody evaluation
โ†’
176.
Recognizing Scope Limitations and Making Appropriate Referrals
intermediatereferralscope of practicetreatment-resistant OCD
โ†’
177.
Billing Compliance and Medical Necessity Documentation
intermediatebilling compliancemedical necessityE/M coding
โ†’
178.
Record Retention Requirements for Psychiatric Records
beginnerrecord retentionpractice closuremedical records
โ†’
179.
Professional Liability Insurance: Claims-Made vs Occurrence Policies
intermediatemalpractice insuranceprofessional liabilityclaims-made
โ†’
180.
HIPAA Compliance and Protected Health Information in Psychiatric Practice
beginnerHIPAAprotected health informationconfidentiality
โ†’
181.
Billing and Coding Compliance: Evaluation and Management Services
intermediatebillingcodingE/M
โ†’
182.
Professional Boundaries and Social Media in Psychiatric Practice
beginnerprofessional boundariessocial mediadual relationships
โ†’
183.
Preceptorship: Training PMHNP Students in Clinical Practice
beginnerpreceptorshipstudent trainingclinical education
โ†’
184.
Health Policy Advocacy and Legislative Engagement in PMHNP Practice
beginnerhealth policyadvocacylegislation
โ†’
185.
Workplace Violence Prevention and Safety in Psychiatric Practice
advancedworkplace violencesafetyde-escalation
โ†’
186.
Steady-State Pharmacokinetics and Half-Life in Clinical Dosing
beginnersteady statehalf-lifepharmacokinetics
โ†’
187.
Receptor Pharmacology: Agonists, Antagonists, and Partial Agonists
intermediatepartial agonistreceptor pharmacologyaripiprazole
โ†’
188.
Augmentation Strategy for Treatment-Resistant Depression
intermediatetreatment-resistant depressionaugmentationaripiprazole
โ†’
189.
CYP2D6 Poor Metabolizer and Antidepressant Selection
hardpharmacogenomicsCYP2D6nortriptyline
โ†’
190.
Valproate Monitoring: Hepatotoxicity and Teratogenicity
intermediatevalproic acidpregnancyteratogenicity
โ†’
191.
Interprofessional Communication During Psychiatric Discharge Planning
intermediateinterprofessional communicationdischarge planningSBAR
โ†’
192.
Augmentation Rationale in Treatment-Resistant Depression
intermediatetreatment-resistant depressionaugmentationSTAR*D
โ†’
193.
Treatment Selection for Bipolar Depression
intermediatebipolar disorderbipolar depressionmood stabilizer
โ†’
194.
PTSD First-Line vs Second-Line Treatment Rationale
intermediatePTSDtrauma-focused therapySSRI
โ†’
195.
OCD Treatment Algorithm: ERP and Medication Integration
hardOCDERPexposure and response prevention
โ†’
196.
Shared Decision-Making in Antipsychotic Selection
intermediateshared decision-makingantipsychoticmetabolic effects
โ†’
197.
Comorbid Anxiety and Substance Use Treatment Prioritization
hardcomorbidityanxietysubstance use disorder
โ†’
198.
Discontinuation Syndrome Prevention Strategies
intermediatediscontinuation syndromeSSRItapering
โ†’
199.
Switching Antidepressant Classes and Washout Period Considerations
hardMAOIserotonin syndromewashout period
โ†’
200.
Metabolic Monitoring Rationale for Atypical Antipsychotics
intermediatemetabolic monitoringatypical antipsychoticschizophrenia
โ†’
201.
Treatment Planning for Comorbid ADHD and Mood Disorder
hardADHDmajor depressive disordercomorbidity
โ†’
202.
Psychotherapy Selection Matching: CBT vs DBT vs EMDR
hardpsychotherapy selectionDBTEMDR
โ†’
203.
Relapse Prevention Planning for Major Depressive Disorder
intermediaterelapse preventionmajor depressive disordermaintenance treatment
โ†’
204.
ACT Defusion Techniques for Intrusive Thoughts
intermediateACTcognitive defusionpsychological flexibility
โ†’
205.
Schema Therapy for Personality Disorders: Limited Reparenting
hardschema therapylimited reparentingpersonality disorders
โ†’
206.
IPT Role Transitions in Depression Treatment
intermediateIPTinterpersonal therapyrole transitions
โ†’
207.
Trauma-Focused CBT: Trauma Narrative with Children
hardTF-CBTtrauma narrativechild sexual abuse
โ†’
208.
Attachment Theory in Adult Therapeutic Relationships
hardattachment theorydismissing attachmentinternal working models
โ†’
209.
Solution-Focused Brief Therapy: The Miracle Question
intermediateSFBTmiracle questionsolution-focused
โ†’
210.
Cognitive Processing Therapy: Stuck Points in PTSD
intermediateCPTcognitive processing therapyPTSD
โ†’
211.
First-Line Treatment Planning for Pediatric ADHD
intermediateADHDpediatricstimulant
โ†’
212.
Antidepressant Selection with Hepatic Comorbidity
hardantidepressanthepatic impairmentSSRI
โ†’
213.
Crisis Intervention and Safety Planning
intermediatesafety planningsuicidal ideationStanley-Brown
โ†’
214.
Integrating Pharmacotherapy with Psychotherapy for PTSD
intermediatePTSDcombined treatmentpsychotherapy
โ†’
215.
Insomnia Treatment in Comorbid Depression
hardinsomniaCBT-Icomorbid insomnia
โ†’
216.
Geriatric Antipsychotic Risk-Benefit Planning
hardgeriatricantipsychoticdementia
โ†’
217.
Bipolar Maintenance Medication Planning
intermediatebipolar disorderlithiummaintenance treatment
โ†’
218.
Collaborative Treatment Planning with Primary Care
intermediatecollaborative careprimary care integrationchronic kidney disease
โ†’
219.
Stages of Change in Substance Use Treatment Planning
intermediatesubstance use disorderopioid use disorderstages of change
โ†’
220.
ECT Indications and Treatment Planning
hardECTpsychotic depressiontreatment-resistant
โ†’
221.
Planning for Medication Non-Adherence
intermediateschizophreniamedication adherencelong-acting injectable
โ†’
222.
Treatment Planning for Comorbid Chronic Pain and Depression
hardchronic paindepressionSNRI
โ†’
223.
Trazodone Mechanism and Dual-Use Rationale
intermediatetrazodoneSARIinsomnia
โ†’
224.
Prazosin Mechanism for PTSD Nightmares
intermediateprazosinPTSDnightmares
โ†’
225.
Gabapentin Off-Label Use and Mechanism
intermediategabapentinalpha-2-deltacalcium channel
โ†’
226.
Aripiprazole Partial Agonist Mechanism
intermediatearipiprazolepartial agonistD2 receptor
โ†’
227.
Mirtazapine Receptor Profile and Clinical Implications
intermediatemirtazapineNaSSAreceptor profile
โ†’
228.
Fluvoxamine Sigma-1 Receptor and Drug Interactions
hardfluvoxamineCYP1A2drug interactions
โ†’
229.
Esketamine (Spravato) Mechanism and Administration
hardesketamineSpravatoNMDA
โ†’
230.
Pimavanserin for Parkinson's Disease Psychosis
hardpimavanserin5-HT2AParkinson's disease psychosis
โ†’
231.
Brexanolone and Neurosteroid Mechanism
hardbrexanoloneZulressoallopregnanolone
โ†’
232.
Deutetrabenazine for Tardive Dyskinesia Mechanism
harddeutetrabenazineVMAT2tardive dyskinesia
โ†’
233.
Vilazodone and Vortioxetine Multimodal Mechanism
hardvortioxetinemultimodalcognitive symptoms
โ†’
234.
Dextromethorphan-Bupropion (Auvelity) Mechanism
harddextromethorphan-bupropionAuvelityNMDA antagonist
โ†’
235.
Clozapine Initiation Criteria and Monitoring
hardclozapinetreatment-resistant schizophreniaREMS
โ†’
236.
Treatment Planning for Refractory OCD
hardOCDtreatment-resistantantipsychotic augmentation
โ†’
237.
Esketamine Treatment Protocol Planning
hardesketamineSpravatotreatment-resistant depression
โ†’
238.
Geriatric Depression Augmentation Strategy
hardgeriatric depressionaugmentationaripiprazole
โ†’
239.
Adolescent Substance Use Treatment Planning
intermediateadolescentsubstance usecannabis
โ†’
240.
Pharmacogenomic-Guided Treatment Planning
hardpharmacogenomicsCYP2D6CYP2C19
โ†’
241.
Comorbid PTSD and SUD Treatment Planning
hardPTSDsubstance use disorderalcohol use disorder
โ†’
242.
Long-Acting Injectable Antipsychotic Planning
hardlong-acting injectablerisperidonepaliperidone
โ†’
243.
TMS Neurostimulation Indications Planning
intermediateTMStranscranial magnetic stimulationtreatment-resistant depression
โ†’
244.
Treatment-Resistant Bipolar Depression Planning
hardbipolar depressiontreatment-resistantquetiapine
โ†’
245.
Collaborative Care Model Implementation
intermediatecollaborative careIMPACT trialprimary care integration
โ†’
246.
Perinatal Depression Treatment Planning
hardperinatal depressionpregnancysertraline
โ†’
247.
Psychiatric Considerations in HIV/AIDS and Antiretroviral Interactions
hardHIV-AIDSdrug-interactionsCYP3A4
โ†’
248.
Severe Bipolar Disorder in Pregnancy: Risk-Benefit Assessment
hardpregnancybipolar-disorderlithium
โ†’
249.
Behavioral Activation vs Full CBT Indications
hardbehavioral activationCBTdepression severity
โ†’
250.
Prolonged Exposure Therapy: Emotional Processing Theory
hardprolonged exposurePTSDemotional processing theory
โ†’
251.
Parent-Child Interaction Therapy: CDI Phase
intermediatePCIToppositional defiant disorderCDI
โ†’
252.
Motivational Enhancement Therapy: Eliciting Change Talk
intermediateMETmotivational interviewingchange talk
โ†’
253.
Supportive vs Exploratory Psychotherapy Indications
intermediatesupportive psychotherapyexploratory psychotherapyego strength
โ†’
254.
Concurrent Buprenorphine and Antidepressant Therapy Planning
hardbuprenorphineantidepressantopioid use disorder
โ†’
255.
Treatment Planning for Catatonia with Lorazepam Challenge
hardcatatonialorazepam challengebenzodiazepines
โ†’
256.
Antidepressant Selection in a Patient with Cardiac Disease
hardcardiacpost-MI depressionsertraline
โ†’
257.
Treatment Planning for Comorbid Epilepsy and Depression
hardepilepsydepressionlamotrigine
โ†’
258.
Treatment Planning for Late-Life Psychosis
hardlate-life psychosisParkinsonismquetiapine
โ†’
259.
Prevention of Serotonin Discontinuation Syndrome
harddiscontinuation syndromeparoxetinetaper strategy
โ†’
260.
Antipsychotic Selection in a Patient with Diabetes
intermediateschizophreniadiabetesmetabolic syndrome
โ†’
261.
Treatment Planning for Pediatric OCD
hardpediatric OCDfluvoxamineCBT
โ†’
262.
Treatment Planning for Treatment-Resistant Anxiety
hardtreatment-resistant anxietyGADbuspirone
โ†’
263.
Planning Cross-Taper Between Antipsychotics
hardcross-taperantipsychotic switchingolanzapine
โ†’
264.
Treatment Planning for Substance-Induced Psychosis
intermediatesubstance-induced psychosismethamphetaminebenzodiazepines
โ†’
265.
Treatment Planning for Comorbid Autism and Aggression
intermediateautismaggressionrisperidone
โ†’
266.
Valproate-Lamotrigine Glucuronidation Interaction
hardvalproatelamotrigineUGT1A4
โ†’
267.
Carbamazepine Enzyme Induction and Oral Contraceptive Failure
hardcarbamazepineoral contraceptivesCYP3A4
โ†’
268.
Disulfiram-Alcohol Reaction Mechanism
harddisulfiramalcohol use disorderaldehyde dehydrogenase
โ†’
269.
Buprenorphine Partial Agonist Ceiling Effect
hardbuprenorphinepartial agonistceiling effect
โ†’
270.
Medication Management Planning for First-Episode Psychosis
hardfirst-episode psychosisantipsychoticssecond-generation antipsychotics
โ†’
271.
Treatment Planning for Comorbid Generalized Anxiety Disorder and Insomnia
hardgeneralized anxiety disorderinsomniacomorbidity
โ†’
272.
Planning for Acute Agitation in Emergency Psychiatric Settings
hardacute agitationemergency psychiatryintramuscular antipsychotics
โ†’
273.
Treatment Planning for Treatment-Resistant Schizophrenia
hardtreatment-resistant schizophreniaclozapineREMS
โ†’
274.
Planning Stepped-Care Model for Depression
hardstepped caredepressiontreatment planning
โ†’
275.
Treatment Planning for Anorexia Nervosa with Comorbid Depression
hardanorexia nervosadepressioneating disorders
โ†’
276.
Planning Medication Management During Breastfeeding
hardpostpartum depressionbreastfeedinglactation
โ†’
277.
Treatment Planning for Acute Mania
hardbipolar disorderacute manialamotrigine
โ†’
278.
Planning Treatment for Comorbid Fibromyalgia and Depression
hardfibromyalgiadepressionduloxetine
โ†’
279.
Treatment Planning for Adolescent Self-Harm
hardadolescentself-harmNSSI
โ†’
280.
Planning Medication Management for Chronic PTSD
hardPTSDsertralineprazosin
โ†’
281.
Treatment Planning for Tardive Dyskinesia Management
hardtardive dyskinesiaVMAT2 inhibitorvalbenazine
โ†’
282.
Motivational Interviewing to Address Medication Adherence Ambivalence
hardmotivational interviewingmedication adherencebipolar disorder
โ†’
283.
Health Literacy Assessment in Psychiatric Medication Education
hardhealth literacyteach-back methodmedication education
โ†’
284.
Therapeutic Communication Techniques With an Angry Patient
hardtherapeutic communicationde-escalationPTSD
โ†’
285.
Population Health Approaches in Psychiatric Nursing Practice
hardpopulation healthdepression screeningquality improvement
โ†’
286.
Trauma-Informed Organizational Practices to Prevent Retraumatization
hardtrauma-informed careorganizational practicesretraumatization prevention
โ†’
287.
Substance Use Harm Reduction Approaches in Outpatient Practice
hardharm reductionopioid use disordernaloxone
โ†’
288.
Peer Support Specialist Integration in Psychiatric Treatment Teams
hardpeer supportteam integrationACT team
โ†’
289.
School Refusal in Pediatric Anxiety: Intervention Planning
hardschool-refusalpediatric-anxietyseparation-anxiety
โ†’
290.
Lamotrigine Dose Adjustments During Pregnancy
hardlamotriginepregnancyUGT1A4
โ†’
291.
Medication Management Challenges in Homeless Populations
hardhomelessnessmedication-adherencelong-acting-injectable
โ†’
292.
Rural Telehealth Psychiatric Care Delivery
hardtelepsychiatryrural-mental-healthcollaborative-care
โ†’
293.
Planning Medication Management for Serotonin Syndrome Prevention
hardserotonin syndromedrug interactionsSNRI
โ†’
294.
Treatment Planning for Social Phobia with Comorbid Avoidant Personality Disorder
hardsocial anxiety disorderavoidant personality disordercomorbidity
โ†’
295.
Planning Treatment for Grief-Related Depression
hardprolonged grief disordermajor depressive disordercomplicated grief treatment
โ†’
296.
Treatment Planning for ADHD in College Students
hardADHDstimulantscollege students
โ†’
297.
Planning Integrated Primary Care and Behavioral Health
hardcollaborative careintegrated careFQHC
โ†’
298.
Treatment Planning for Dissociative Identity Disorder
harddissociative identity disorderphase-oriented treatmenttrauma
โ†’
299.
Planning Withdrawal Management for Polysubstance Use
hardpolysubstance withdrawalalcohol withdrawalbenzodiazepine withdrawal
โ†’
300.
Treatment Planning for Chronic Suicidality in Borderline Personality Disorder
hardborderline personality disorderchronic suicidalityDBT
โ†’
301.
Planning Pharmacotherapy for Postpartum Psychosis
hardpostpartum psychosislithiumbipolar disorder
โ†’
302.
Treatment Planning for Conversion Disorder
hardconversion disorderfunctional neurological disorderpsychoeducation
โ†’
303.
Planning Treatment for Body Dysmorphic Disorder
hardbody dysmorphic disorderSSRICBT
โ†’
304.
Treatment Planning for Co-Occurring Chronic Illness and Depression
harddiabetesneuropathic painduloxetine
โ†’
305.
Planning Discharge and Transition of Care
harddischarge planningtransition of carelong-acting injectable
โ†’
306.
Planning Medication Adjustment for Renal Impairment
hardlithium nephropathyrenal impairmentmood stabilizer
โ†’
307.
Planning Trauma-Focused Treatment Sequencing
hardcomplex PTSDtrauma treatmentphased model
โ†’
308.
Exposure and Response Prevention for OCD Contamination Subtype
intermediateCBTOCDexposure and response prevention
โ†’
309.
Cognitive Restructuring Techniques for Generalized Anxiety Disorder
intermediateCBTGADcognitive restructuring
โ†’
310.
OARS Techniques in Motivational Interviewing for Substance Use
intermediatemotivational interviewingOARSsubstance use
โ†’
311.
Stages of Change and Motivational Interviewing Strategies
intermediatemotivational interviewingstages of changetranstheoretical model
โ†’
312.
Yalom's Therapeutic Factor of Universality in Group Therapy
intermediategroup therapyYalomtherapeutic factors
โ†’
313.
Instillation of Hope and Altruism in Group Therapy
hardgroup therapyYalomtherapeutic factors
โ†’
314.
DBT Distress Tolerance Skills for Crisis Situations
intermediateDBTdistress toleranceTIPP
โ†’
315.
DBT Interpersonal Effectiveness and Emotion Regulation Integration
hardDBTemotion regulationinterpersonal effectiveness
โ†’
316.
Trauma-Informed Care Principles and Retraumatization Prevention
intermediatetrauma-informed carecomplex PTSDretraumatization
โ†’
317.
Organizational Trauma-Informed Care Implementation
hardtrauma-informed careorganizational implementationSAMHSA
โ†’
318.
Identifying and Addressing Therapeutic Alliance Rupture
hardtherapeutic alliancerupturewithdrawal
โ†’
319.
Therapeutic Alliance Repair Following Confrontation Rupture
hardtherapeutic alliancerupture repairconfrontation rupture
โ†’
320.
Lamotrigine Titration and Stevens-Johnson Syndrome Risk
intermediatelamotrigineStevens-Johnson syndromemood stabilizer
โ†’
321.
Clozapine Monitoring Requirements and Agranulocytosis
intermediateclozapineREMSagranulocytosis
โ†’
322.
Hepatic Impairment and Psychotropic Dose Adjustment
hardhepatic impairmentcirrhosisantidepressant
โ†’
323.
QTc Prolongation Risk in Antipsychotic Selection
hardQTc prolongationantipsychoticaripiprazole
โ†’
324.
Pediatric ADHD Comprehensive Assessment
intermediateADHDpediatric assessmentVanderbilt scales
โ†’
325.
Pediatric ADHD Medication Management and Stimulant Selection
intermediateADHDstimulant medicationsmethylphenidate
โ†’
326.
Geriatric Depression with Comorbid Cognitive Decline Differential Diagnosis
hardgeriatric depressionpseudodementiacognitive decline
โ†’
327.
Geriatric Depression SSRI Management and Safety Considerations
hardgeriatric depressionSSRI managementdrug interactions
โ†’
328.
Pregnancy Psychopharmacology SSRI Risk-Benefit Analysis
hardpregnancypsychopharmacologysertraline
โ†’
329.
Lactation Psychopharmacology and Medication Selection
intermediatepostpartum depressionlactationbreastfeeding
โ†’
330.
Adolescent Self-Harm Assessment and Risk Stratification
hardadolescentself-harmNSSI
โ†’
331.
Adolescent Self-Harm Safety Planning and Family Intervention
hardadolescentself-harmsafety planning
โ†’
332.
Geriatric Alcohol Use Disorder Screening and Treatment Initiation
hardgeriatricalcohol use disordermotivational interviewing
โ†’
333.
Geriatric Benzodiazepine Use Disorder and Deprescribing
hardgeriatricbenzodiazepinedeprescribing
โ†’
334.
Autism Spectrum Disorder with Comorbid Anxiety in a Child
intermediateautism spectrum disorderASDanxiety
โ†’
335.
ASD Adolescent Irritability and Aggression Pharmacological Management
intermediateautism spectrum disorderASDirritability
โ†’

Other AANPCB domains

๐Ÿ”Ž Assess (33%)๐Ÿงฉ Diagnose (21%)๐Ÿ“Š Evaluate (20%)

Want to understand the full AANPCB blueprint? Read the complete AANPCB exam guide โ†’

โ† AANPCB Board Prep